Sever Clint covered exercise/tax liability with 12,604 shares, decreasing direct ownership by 0.29% to 4,400,370 units (SEC Form 4)

$HLTH
Biotechnology: Laboratory Analytical Instruments
Industrials
Get the next $HLTH alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sever Clint

(Last) (First) (Middle)
C/O CUE HEALTH INC.
4980 CARROLL CANYON RD. SUITE 100

(Street)
SAN DIEGO CA 92121

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cue Health Inc. [ HLTH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Product Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/05/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/05/2024 F 12,604 D $0.25 4,400,370(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Includes 1,132,676 unvested RSUs.
Remarks:
/s/ Joshua Bergmann, Attorney-in-Fact for Clint Sever 03/07/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $HLTH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HLTH

DatePrice TargetRatingAnalyst
3/14/2024Buy → Neutral
BTIG Research
10/19/2021$18.00Buy
BTIG Research
10/19/2021$12.00Equal-Weight
Morgan Stanley
10/19/2021$19.00Buy
Goldman Sachs
10/19/2021$14.00Outperform
Cowen & Co.
More analyst ratings

$HLTH
Press Releases

Fastest customizable press release news feed in the world

See more
  • Cue Health to Pursue Wind Down of the Business

    Cue Health Inc. ("Cue" or the "Company") (NASDAQ:HLTH), a healthcare technology company, today announced the Company has filed voluntary petitions under Chapter 7 of the U.S. Bankruptcy Code in the District of Delaware to pursue a wind down of its business. Cue has been working diligently to strengthen the Company's financial foundation, including taking a number of actions to reduce costs and improve operational efficiency. Cue also undertook an extensive process to locate additional financing or effect a strategic transaction. Despite its best efforts and after a comprehensive review, Cue's Board of Directors in consultation with the Company's advisors, has concluded that it is in the b

    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Cue Health Evaluating Warning Letter Received from Food and Drug Administration (FDA)

    Cue Health Inc. (NASDAQ:HLTH), a healthcare technology company (the "Company"), has received a warning letter from the FDA about its Emergency Use Authorized (EUA) COVID-19 test. The Company is currently evaluating the letter and determining its response, with more information to follow in the next few days. About Cue Cue Health Inc. (NASDAQ:HLTH) is a healthcare technology company that empowers healthcare providers to streamline their ability to deliver value-based care with fast, highly accurate test results on demand. Cue received De Novo authorization from the U.S. Food and Drug Administration (FDA) for its COVID-19 test, which became the first home use respiratory test to receive t

    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Cue Health to Announce First Quarter Financial Results

    Cue Health Inc. ("Cue") (NASDAQ:HLTH), a healthcare technology company, announced today that it will release its first quarter 2024 financial results on Monday, May 13, 2024. The company will not be hosting a conference call. About Cue Health Cue Health Inc. (NASDAQ:HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. Cue's platform offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a wide range of health and wellness needs. Cue's customers include fede

    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$HLTH
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$HLTH
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$HLTH
SEC Filings

See more

$HLTH
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$HLTH
Leadership Updates

Live Leadership Updates

See more
  • Cue Health Announces Strategic Actions to Position Company for Next Stage

    Clint Sever Appointed CEO Board Appoints Two Strategic Advisors Who Bring Significant Industry Expertise Cue Health Inc. ("Cue" or the "Company") (NASDAQ:HLTH), a healthcare technology company, today announced strategic actions implemented by its Board of Directors (the "Board") to best position the Company for its next stage: Clint Sever, co-founder and current Chief Product Officer, has been appointed CEO, effective immediately. Sever succeeds Ayub Khattak, who is stepping down as Chief Executive Officer, President, and Chairman. Khattak will remain a member of the Board of Directors. The Board has appointed two strategic advisors, who have specific subject matter expertise in i

    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Cue Health Announces Appointment of Rishi Reddy to Board of Directors

    Cue Health (NASDAQ:HLTH), a healthcare technology company, today announced it entered into a cooperation agreement (the "Cooperation Agreement") with Tarsadia Investments ("Tarsadia"), and appointed Rishi Reddy to its board of directors (the "Board"), effective immediately. Mr. Reddy is a Managing Director at Tarsadia, where he leads the firm's venture and growth equity strategy. He was previously an Observer on Cue's Board of Directors from April 2018 to September 2021. In addition, the Board intends to commence a process to add an additional highly qualified, independent director to the Board. "Cue remains focused on creating value for all of its stakeholders," said Ayub Khattak, Chairm

    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Cue Health Announces Appointment of Josh Ghaim, Ph.D. and Sachin Jain, M.D. to its Board of Directors

    Cue Health ("Cue") (NASDAQ:HLTH), a healthcare technology company that puts diagnostic information at the center of care, today announced that Josh Ghaim, Ph.D. and Sachin Jain, M.D. have joined its Board of Directors. Cue Health's Board now consists of seven directors, five of whom are independent. "On behalf of the management team and Board, I'm pleased to welcome both Josh and Sachin to the Cue team. We are excited to have vast knowledge of health plans and payors as well as the perspective of a medical doctor on Cue's Board as we continue to pursue our vision of making healthcare more convenient, accessible, and timely by placing diagnostic information at the center of care," said Ayub

    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$HLTH
Financials

Live finance-specific insights

See more
  • Cue Health to Announce First Quarter Financial Results

    Cue Health Inc. ("Cue") (NASDAQ:HLTH), a healthcare technology company, announced today that it will release its first quarter 2024 financial results on Monday, May 13, 2024. The company will not be hosting a conference call. About Cue Health Cue Health Inc. (NASDAQ:HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. Cue's platform offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a wide range of health and wellness needs. Cue's customers include fede

    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Cue Health Reports Fourth Quarter 2023 Financial Results

    Cue Health Inc. ("Cue" or the "Company") (NASDAQ:HLTH), a healthcare technology company, today reported financial results for the fourth quarter and full-year 2023. Recent Highlights Reported fourth quarter total revenue of $18.8 million. Full-year 2023 total revenue was $70.9 million Submitted additional clinical samples and stability data for RSV to the FDA in support of de novo submission Submitted additional clinical samples and gathering additional stability data for Flu A/B to the FDA in support of de novo submission In late stage development of Herpes + Mpox Multiplex Molecular Test with plan to submit for EUA in 2Q24 Executed cost reduction plans, resulting in cash

    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Cue Health to Announce Fourth Quarter and Full Year 2023 Financial Results

    Cue Health Inc. ("Cue") (NASDAQ:HLTH), a healthcare technology company, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, March 13, 2024. In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call. The live webinar of the call may be accessed by visiting the Events

    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$HLTH
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more